We are currently conducting research and development activities in order to facilitate the transition of the patent technology we license from the laboratory to clinical trials. Our planned principal operations are the development and commercialization of new cell therapy products focused on treatment of blood cancers, nonmalignant blood disorders and organ transplantations.